TGF-β presents a target for antitumor therapy as well its inhibition using SD208 or galunisertib (LY3200882) as the invasion of CD8+ T lymphocytes is increased and tumor growth is inhibited [149]. The gene discussed is CD8A; the disease is neoplasm.